MTS: The Perspectives

Outside Opinion: We’re Just Talking . . . With Jay Watkins

Outside Opinion: We’re Just Talking . . . With Jay Watkins

In this new installment of his series of interviews on corporate governance in medtech, DeNovo Ventures’ Managing Director Joe Mandato speaks with Jay Watkins, also a Managing Director at De Novo Ventures and at Curation Capital.​ Jay has served in multiple board roles and shares his insights on what makes a good board tick.

Perspective: MedTech in the Military - Saving Lives On and Off the Battlefield

Perspective: MedTech in the Military - Saving Lives On and Off the Battlefield

Driven by his passion to take care of the people who willingly put their lives on the line, Medical Technology Enterprise Consortium’s COO, William Howell, talks to the Community Blog about the goals of MTEC, and cutting-edge biomedical research that has recently received funding through this US Army organization. Although research is primarily focused on restoring function to severely injured soldiers, many of the medical technologies originally developed by or with funding support from the US military are also impacting the lives of millions of civilian patients.

Decibel Therapeutics Turns up the Volume on Hearing Loss

Decibel Therapeutics Turns up the Volume on Hearing Loss

There are about 466 million people worldwide with disabling hearing loss, 48 million of them in the US. To date, hearing aid devices have been the only solution to sensorineural hearing loss, the kind that comes from aging and the dam­age loud sounds cause. Eyeing the potential blockbuster opportunity, pharmaceutical companies like Decibel Therapeutics have finally joined the fray.

ICYMI: Can Advanced Implant Materials Best Biologics?

ICYMI: Can Advanced Implant Materials Best Biologics?

Robotics were the hot topic at NASS 2018, but discussions also raged about advanced implant materials that have the potential to promote better bone growth and faster healing and reduce reliance on expensive biologics to achieve those goals.  An excerpt from Senior Writer Wendy Diller’s November 16 feature, “At NASS 2018, Advanced Biomaterials and the Pull of Robots.”

ICYMI: CardiacSense: A New Wearable Diagnostic for AF

ICYMI: CardiacSense: A New Wearable Diagnostic for AF

Apple recently made a splash with its new ECG-enabled watch, but technology from an Israeli start-up may have a better chance of penetrating the multibillion-dollar ambulatory cardiac arrhythmia monitoring market. An excerpt from Executive Editor Mary Thompson’s October 31 feature, “Ambulatory ECG Monitoring Enters a New, More Patient-Friendly Era.”

Perspective: Today’s Medical Device Supply Chain – Part 2: The Potential “Amazonification” of an Industry

Perspective: Today’s Medical Device Supply Chain – Part 2: The Potential “Amazonification” of an Industry

Behemoth online retailer Amazon is setting its powerful sights on the medical device supply chain. Will the Internet giant have the resolve to invest in the competencies and infrastructure necessary to meet the regulatory demands of healthcare logistics? It faces a number of tailwinds and headwinds in its run at disrupting the healthcare market, says Larry Smith, retired Vice President, Global Supply Chain at BD.

Perspective: Today’s Medical Device Supply Chain – Part 1: Industry Innovator

Perspective: Today’s Medical Device Supply Chain – Part 1: Industry Innovator

Innovation in the device space isn’t just about next-generation technologies—it also defines the forward-thinking role of today’s medical device supply chain. Here, we look at three key issues impacting supply chain organizations that companies of all sizes need to pay attention to as they grow, expand into developing markets, and as the industry consolidates, according to industry veteran Larry Smith, retired VP, Global Supply Chain at BD. One potential game-changer on the horizon: Amazon.

ICYMI: New FDA Regs Provide Clarity and Confusion for Orthobiologics Manufacturers

ICYMI: New FDA Regs Provide Clarity and Confusion for Orthobiologics Manufacturers

Last November, FDA issued a long-awaited, final guidance on its standards for overseeing human cell and tissue products. It is the latest move in an ongoing effort by the agency to wrap its arms around the complex, evolving, and controversial area of tissue-based biologics and, by extension, the newer, fast-growing field of regenerative medicine. An excerpt from Senior Writer Wendy Diller’s October 17 feature, “Regulatory Shifts for HCT/P Products Put Orthobiologics Manufacturers on the Spot.”

Apple’s ECG App and the Advantages of Scale

Apple’s ECG App and the Advantages of Scale

Sloan Gaon, CEO of PulsePoint, a programmatic health technology company that uses data and technology to engage consumers and personalize healthcare advertising on the web, talks with the Community Blog about how the new Apple Watch and other tech and data initiatives are driving the shift to “radical health personalization.”

Expert Perspective: The Community Blog Checks In with Jeffrey Shuren

Expert Perspective: The Community Blog Checks In with Jeffrey Shuren

At the recent MedTech Conference powered by AdvaMed, held in Philadelphia, the Community Blog caught up with Jeffrey Shuren, MD, JD, Director, Center for Devices and Radiological Health (CDRH) at the FDA. We asked him what he thought about today’s medical device regulatory climate, and where he sees the industry overall headed in the next few years. Hint: Shuren’s optimistic vision for the future of the CDRH embodies the overall theme of everything we do here at the Community Blog - build a community. Our Q&A is included below.

Outside Opinion: "We’re Just Talking With . . . Fred Moll"

Outside Opinion: "We’re Just Talking With . . . Fred Moll"

DeNovo Ventures’ Managing Director Joe Mandato speaks with minimally invasive surgery/robotics pioneer Fred Moll, MD. Moll founded three public robotics companies, co-founded Origin MedSystems and Gynecare, and recently raised a record amount of capital for a new device company, Auris Health. Moll is an innovator, entrepreneur, and seasoned board member, and he speaks with Mandato about board governance.

ICYMI: Digital Biomarkers of Neurological Function

ICYMI: Digital Biomarkers of Neurological Function

Neuro-focused prescription digital health companies are taking aim at a range of diseases from psychiatric and mental health disorders to neurodegenerative diseases. In this excerpt from our September 28 feature, “Digital Taps Into Neurological Function,” Mark Ratner talks with William Marks, MD, about Verily Life Sciences’ activities in the field.

gBETA Medtech Accelerator – Filling a Critical Gap for Start-Ups

gBETA Medtech Accelerator – Filling a Critical Gap for Start-Ups

gBETA Medtech Accelerator, launched this past March, is the first accelerator of its kind to tap into the rich medical device, digital healthcare, diagnostics and biotech ecosystem that exists in the Midwest Medical Alley region. Its goal is community building, and fostering innovation among the most promising of today’s early-stage start-ups. The program is funded by Boston Scientific, with additional support from Mayo Clinic, University of Minnesota, and Medical Alley Association.